A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA)
inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two
puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC) inhalation
aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The dose response
profile, safety and pharmacokinetics of Combivent HFA formulation are to be characterized.